Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy

R. Vojtíšek, J. Baxa, P. Kovářová, A. Almortaza, P. Hošek, E. Sukovská, R. Tupý, J. Ferda, J. Fínek

. 2021 ; 197 (6) : 494-504. [pub] 20210125

Language English Country Germany

Document type Comparative Study, Journal Article

Grant support
CZ.02.1.01/0.0/0.0/17_048/0007280) Lékařská Fakulta v Plzni, Univerzita Karlova

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2006-08-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago
Public Health Database (ProQuest) from 1997-01-01 to 1 year ago

PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV‑S, pre-TLG, pre-TLG‑S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV‑S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-∆ and ∆%. We divided the whole group of patients into "responders" (CMR) and "non-responders" (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG‑S, mid-MTV‑S, mid-tumor size, and ∆%SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV‑S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV‑S and mid-TLG‑S and between mid-MTV and mid-TLG, were found (all p < 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV‑S, mid-MTV, mid-tumor size, mid-TLG‑S, mid-TLG and ∆%SUVmax.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025700
003      
CZ-PrNML
005      
20211026133602.0
007      
ta
008      
211013s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00066-020-01740-7 $2 doi
035    __
$a (PubMed)33492444
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vojtíšek, Radovan $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic. vojtisekr@fnplzen.cz
245    10
$a Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy / $c R. Vojtíšek, J. Baxa, P. Kovářová, A. Almortaza, P. Hošek, E. Sukovská, R. Tupý, J. Ferda, J. Fínek
520    9_
$a PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV‑S, pre-TLG, pre-TLG‑S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV‑S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-∆ and ∆%. We divided the whole group of patients into "responders" (CMR) and "non-responders" (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG‑S, mid-MTV‑S, mid-tumor size, and ∆%SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV‑S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV‑S and mid-TLG‑S and between mid-MTV and mid-TLG, were found (all p < 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV‑S, mid-MTV, mid-tumor size, mid-TLG‑S, mid-TLG and ∆%SUVmax.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alkylační protinádorové látky $x terapeutické užití $7 D018906
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a brachyterapie $7 D001918
650    _2
$a spinocelulární karcinom $x diagnostické zobrazování $x metabolismus $x patologie $x terapie $7 D002294
650    12
$a chemoradioterapie $7 D059248
650    _2
$a cisplatina $x terapeutické užití $7 D002945
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a počítačové zpracování obrazu $7 D007091
650    _2
$a ozařování lymfatického systému $7 D015182
650    _2
$a lymfatické metastázy $7 D008207
650    12
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a lidé středního věku $7 D008875
650    12
$a multimodální zobrazování $7 D064847
650    _2
$a staging nádorů $x metody $7 D009367
650    12
$a pozitronová emisní tomografie $7 D049268
650    _2
$a prognóza $7 D011379
650    _2
$a ROC křivka $7 D012372
650    _2
$a radioterapie s modulovanou intenzitou $7 D050397
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
650    _2
$a nádory děložního čípku $x diagnostické zobrazování $x metabolismus $x patologie $x terapie $7 D002583
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baxa, Jan $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Kovářová, Petra $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Almortaza, Amira $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Hošek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300, Pilsen, Czech Republic
700    1_
$a Sukovská, Emília $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Tupý, Radek $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Ferda, Jiří $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
700    1_
$a Fínek, Jindřich $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
773    0_
$w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] $x 1439-099X $g Roč. 197, č. 6 (2021), s. 494-504
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33492444 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133608 $b ABA008
999    __
$a ok $b bmc $g 1714649 $s 1146207
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 197 $c 6 $d 494-504 $e 20210125 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
GRA    __
$a CZ.02.1.01/0.0/0.0/17_048/0007280) $p Lékařská Fakulta v Plzni, Univerzita Karlova
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...